Letters to the Editor

Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan
Maria Skłodowska-Curie National Research Institute of Oncology, Kraków
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
Medical University of Łódź, Łódź
Fred Hutchinson Cancer Research Center, Seattle, WA
Alfred Hospital and Monash University, Melbourne, VIC
State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
BeiGene USA, Inc, San Mateo, CA
BeiGene International GmbH, Basel
BeiGene (Shanghai) Co, Ltd, Shanghai
BeiGene USA, Inc, San Mateo, CA
BeiGene USA, Inc, San Mateo, CA
BeiGene USA, Inc, San Mateo, CA
BeiGene USA, Inc, San Mateo, CA
ASST Grande Ospedale Metropolitano Niguarda, Milan
Vol. 109 No. 7 (2024): July, 2024 https://doi.org/10.3324/haematol.2023.283846